**Supplementary Appendix 1**. Reasons for HCWs not being eligible for the COVID-19 VE analysis\*

|  |  |
| --- | --- |
| 18,359 HCWs |  |
|   |  |  |
|   |   | 225 HCWs with one dose of COVID-19 vaccine in 2020 (Clinical Trial) |
|   |  |  |
|   |   | 2,945 HCWs contracted COVID-19 infection prior to the study (before the COVID-19 vaccine). Of that 28 HCWs received Pfizer COVID-19 vaccine  |
|   |  |  |
|   |   | 79 HCWs contracted Covid-19 between 0 and 14 days of the COVID-19 vaccine first dose |
|   |  |  |
|   |   | 159 unvaccinated HCWs with COVID-19 with before 01/15/2021 |
|   |  |  |
|   |   | 50 HCWs received CoronaVac or Pfizer with less than 15 days between the COVID-19 doses (the first and the second dose). Of that 49 HCWs received Coronavac and one HCW received Pfizer |
|   |  |  |
|   |   | 27 HCWs received Oxford-AstraZeneca vaccine with less than 50 days between the COVID-19 doses (the first and the second dose)  |
|   |  |  |
|   |   | 789 HCWs without the COVID-19 vaccine second dose (being 102 HCWS that received Pfizer COVID-19 vaccine) |
|   |  |  |
|   |   | 218 HCWs contracted COVID-19 infection between 15 days between the first and the second dose of COVID-19 vaccine |
|   |  |  |
|   |   | 50 HCWs contracted COVID-19 between 0 and 14 days of COVID-19 vaccine second dose |
|   |  |  |
|   |   | 4 HCWs with less than 14 days of follow-up  |
|   |  |  |
| 13,813 HCWs |  |

\*131 HCWs vaccinated with Pfizer COVID-19 vaccine were not included in the VE analysis because of the small sample and because of the second dose is taken 12 weeks apart. Of that 102 HCWs got the first COVID-19 vaccine dose, 28 HCWs got COVID-19 infection before the first COVID-19 vaccine dose, and one HCW had taken the COVID-19 vaccine 14 days of interval between the two doses.